The survival rate of lung cancer remains low despite the progress of surgery and chemotherapy. With the increasing comorbidity of obesity in patients with lung cancer, new challenges are emerging in the management of this patient population. A key issue of interest is the prognostic effect of obesity on surgical and chemotherapeutic outcomes in patients with lung cancer, which is fueled by the growing observation of survival benefits in overweight or obese patients. This unexpected inverse relationship between obesity and lung cancer mortality, called the obesity paradox, remains poorly understood. The evolving insights into the heterogeneity of obesity phenotypes and associated biological connections with lung cancer progression in recent years may help explain some of the seemingly paradoxical relationship, and well-designed clinical studies looking at the causal role of obesity-associated molecules are expected. Here, we examine potential biological mechanisms behind the protective effects of obesity in lung cancer. We highlight the need to clarify the clinical implications of this relationship toward an updated intervention strategy in the clinical care of patients with lung cancer and obesity.
Introduction
The adverse effects of obesity on health have long been recognized, and much attention has been focused on how to tackle this global epidemic to reduce the risk for many diseases. In the clinical scenario, obesity is an essential factor in designing treatment regimens and predicting prognosis. However, at this established stage, the impact of obesity seems not so straightforward and there is emerging realization that obesity is not necessarily a poor prognostic factor as previously thought. Of interest, it has been found that, for several diseases, an "obesity paradox" exists, where being obese actually predicts better clinical outcomes. [1] [2] [3] In the field of clinical oncology, this unexpected inverse relationship is typically found in patients with lung cancer, which is highlighted by an emerging number of recent publications. [4] [5] [6] Being overweight or obese, largely with body mass index (BMI) falling within the range from 25 to 34.9 kg/m 2 , may actually be protective and associated with reduced mortality in patients with lung cancer after surgery or chemotherapy. This contrasts the epidemiological evidence linking obesity with poor survival for several other types of cancer (e.g., colon, leukemia). [7] [8] [9] [10] Lung cancer is one of the leading malignancies and causes of death worldwide, 11 and obesity has become a major risk factor for cancer. Given the increasing comorbidity of obesity and lung cancer, new complexity lies ahead for thoracic oncologists to deliberate on the exact impact of obesity on lung cancer treatment and survival. [12] [13] [14] Doubts about whether there is truly an obesity paradox in lung cancer and other diseases have long been lingering. The criticisms are largely seen around the improper use of BMI in obesity classification, and the discussion of BMI-based measurement of obesity as a confounding factor has been covered elsewhere.
nutritional status, and comorbidities have been considered in the observational data. 17 It is clear that the obesity paradox is unlikely to be explained by the confounding factor alone. Is there any biological mechanism that might contribute to this paradoxical link between obesity and lung cancer prognosis? In recent years, the accumulated insights into the biology of obesity and interorgan crosstalk in lung cancer have provided some hints for answering this critical question. In this review, we first provide a brief look at the representative clinical reports that continuously consolidate the nondeleterious effects of obesity in lung cancer prognosis. We then discuss potential biological plausibility, which may help in understanding the survival advantage in obese patients with lung cancer. Lastly we focus on the implications for clinical management of patients with lung cancer, highlighting the need for a conceptual update on interpreting obesity for better treatment and care of these special patients.
Prognostic Effect of Obesity on Lung Cancer: Where Do We Stand?
For patients with lung cancer, it is a common presumption that obese patients are more susceptible to postoperative complications because of potentially decreased diaphragm excursion, reduced lung volumes, and relative immobility. 18, 19 However, observational data in patients with lung cancer have largely established a nonrelevant or inverse relationship. For example, in a retrospective data analysis of 6567 patients with lung cancer who underwent lung resection, overweight and mildly obese patients were not predisposed to greater mortality and morbidity after lung resection. 20 Another retrospective study of 19,635 patients with primary lung cancer undergoing lobectomy reported that underweight patients experienced significantly more pulmonary, surgical, and infectious complications than their overweight counterparts did. 16 These reports are part of the prevailing evidence that obese patients do not necessarily have higher risks, and they may even have a survival advantage after surgical intervention for lung cancer (Table 1) . This was recently confirmed by a systematic review of 25 observational studies with 78,143 patients, which found that obesity has favorable effects on in-hospital outcomes and longterm survival of surgical patients with lung cancer. 27 On the other hand, there are also few reports showing no evidence of outcome benefits in overweight or moderately obese individuals, 24 although it should be noted that these are based on results from a single center with small sample sizes. Indeed, a very recent analysis of 41,446 patients who underwent lung resection for cancer shows that being underweight or severely overweight is associated with an increased risk for complications. 28 Therefore, obesity is more likely to have a protective effect on lung cancer outcome in patients with a BMI approximating those indicating overweight or normal obesity.
Compared with the study of surgical outcome, fewer reports are available on the prognostic effect of obesity on chemotherapeutic outcomes. An early study involving 262 patients with SCLC found that obesity at the start of treatment was not associated with increased toxicity or a shortened survival. 29 More recently, a retrospective study of 127 patients with lung cancer who were receiving carboplatin showed similar results, namely, that there was no difference in median overall survival or toxicity with a BMI cutoff value at 25 kg/m 2 . 30 Therefore, the impact of obesity on overall survival in lung cancer seems to be not as detrimental as supposed. One of the latest retrospective studies, which included 200 patients with lung cancer, also found that a decrease in BMI during the chemotherapy cycles was actually associated with poor survival. 31 Collectively, these repeatedly observed data suggest a high biological plausibility of the obesity paradox. Although some potential methodological factors (e.g., sample representativeness, control for lifestyle factors, length of the clinical observation) in the clinical studies may be considered, 32 two recent systematic reviews specifically addressing these potential confounding issues have identified the same protective effects of obesity in lung cancer outcome. 4, 27 Therefore, it is necessary to examine the pathophysiologic mechanisms that contribute to this inverse relationship in the management of patients with lung cancer and different BMIs.
What Are the Potential Biological Mechanisms?
The concept of the obesity paradox was initially observed for diseases such as heart failure 1 and end-stage kidney failure, 33 but the mechanisms behind this paradoxical relationship are still not fully understood. 3, 34, 35 With respect to the biological mechanisms that might explain the obesity paradox in cancer, the metabolic and endocrinal landscape of obesity that may modify the association between BMI and mortality could be take into consideration. Moreover, it would be useful to look at the potential counteracting effects of obesity on the adverse factors in lung cancer outcome. Here we summarize recent evidence illustrative of the biological basis of the obesity paradox in lung cancer prognosis (Fig. 1) .
Metabolically Healthy Obesity and Physical Fitness
Obesity is an established adverse factor in the onset of many chronic diseases at the population level. Nevertheless, it has been found that a proportion of obese individuals might not be at increased risk for metabolic complications of obesity despite a high BMI. 36, 37 This has led to the novel idea of "metabolically healthy obesity" to explain the unexpected low disease risk in some obese populations. 38, 39 Individuals with metabolically healthy obesity are a subset of obese individuals (defined by BMI >30 kg/m 2 ) who are believed to be at much lower risk for cardiovascular morbidity and mortality. 38 Studies from genetically modified mouse models reveal that metabolic healthy obesity is accompanied by an increased mass of nonvisceral adipose tissue 40 and a metabolically beneficial adipokine pattern. 41 Likewise, human studies show that the metabolically healthy obesity phenotype is associated with favorable fat distribution patterns, reduced adipose tissue inflammation, and increased cardiorespiratory fitness. 42, 43 These facts suggest that metabolically healthy obesity could be viewed as a potential modifier of the adverse association between obesity and mortality.
The existence of metabolically healthy obesity carries important implications for understanding the obesity paradox in lung cancer. A prospective cohort study involving 43,265 participants reported that metabolically healthy obese individuals had lower cancer mortality than their metabolically unhealthy obese peers did. 44 In theory, patients having metabolically healthy obesity exhibit a generally better health status in terms of metabolic and immune homeostasis despite a higher BMI, which is a favorable condition for prognosis. Moreover, higher level of physical fitness may contribute to better tolerance to toxic therapeutics and surgical stresses and therefore improved survival in the long term, 45 which is reminiscent of the contribution of cardiorespiratory fitness to better survival in some obese patients with cardiovascular disease. These emerging insights into the heterogeneity of obesity suggest that additional molecular characterizations of obese phenotypes in patients with lung cancer may help in understanding the differences in mortality at an individual level.
Adipokines and Endocrine Changes
Adipose tissue is an endocrine organ that secretes numerous bioactive molecules known as adipokines. Obese patients tend to have higher circulating levels of adipokines such as leptin and adiponectin, which should not be overlooked as a potential modifier of the inverse association between obesity and mortality. The involvement of certain adipokines in lung cancer prognosis has indeed been suggested by a growing body of evidence. For example, serum leptin level has been reported as an independent prognostic factor for lung cancer survival. Specifically, patients with lower values of serum leptin were found to have shorter overall survival with untreated lung cancer. 46 This suggests that obese patients with a higher serum leptin level may have a survival advantage. Adiponectin, which has been implicated in the apoptosis and metastasis of tumor cells, is possibly another mediator mediating the protective effect of obesity on lung cancer survival. For NSCLC, adiponectin is a potential contributor to tumor progression and has been suggested as a potential diagnostic and prognostic biomarker. 47 As such, it is not surprising to find that some obese patients with low adiponectin levels have a better prognosis after lung cancer treatment. Of interest, it is also recently reported that circulating adiponectin levels are inversely correlated with BMI and directly correlated with the obesity paradox observed in patients with renal cell carcinoma. 48 This is in line with a previous report on patients with renal cell carcinoma showing that tumor development in an obesogenic environment may become less aggressive. 49 This epidemiological study also correlated genomewide signatures of tumor with BMI and survival; fatty acid metabolic genes, especially the fatty acid synthase gene (FASN), were found to underlie the differential outcomes of tumor. These findings suggest that it would be interesting to investigate the molecular features of lung cancer in obese patients to better understand the obesity paradox in this scenario.
In addition to endocrinal changes from adipose tissue, the potential effect of therapeutic drugs that may change the endocrinal landscape and tumor aggressiveness has been suggested in obese patients. For example, it was shown that statin use after a lung cancer diagnosis was highly associated with increasing BMI and predicted improved survival. 26 However, a recent populationbased study of 533 patients has clarified that there is no protective association between antidiabetic Figure 1 . Potential biological mechanisms contributing to the obesity paradox in lung cancer. Factors that may contribute to better prognosis in lung cancer include the following: (1) patients with metabolically healthy obesity or physiological fitness may not suffer from the detrimental effects of obesity-associated metabolic disturbance; (2) adipose tissue may provide greater physiological and nutritional reserves, thereby prolonging life by slowing the progress of cancer cachexia; and (3) some adipokines from the adipose tissue may produce tumor-suppressing effects and, therefore, survival advantages. However, the presence of cachexia and presence of sarcopenia, which are characterized by massive and progressive muscle and fat loss, are established as predictors of poor prognosis of lung cancer. These biological mechanisms may partially explain the inverse relationship between body mass index (BMI) and lung cancer outcome. medication (including sulfonylureas, insulin or thiazolidinediones, and metformin) and cancer mortality in patients with lung cancer. 50 
Cachexia, Sarcopenia, and Unhealthy Lean
Cachexia, a wasting status with devastating effect on quality of life and survival, is a common condition observed in patients with lung cancer. 47 Notably, patients with NSCLC experience cachexia at a high incidence of 61%, which is an established adverse factor for survival. 51 Sarcopenia, which involves skeletal muscle wasting characterized by atrophy and weakness, is a major contributor to the weight loss in cancer cachexia. Importantly, muscle loss in cancer cachexia is known to cause physical decline, psychological stress, and poor responses to chemotherapy, exerting an independent adverse effect on patient survival with various types of cancer. 52 This is in line with the clinical data that patients with sarcopenia had a significantly worse outcome than patients without sarcopenia did. Indeed, sarcopenia identified by cross-sectional computed tomography (CT) image has been confirmed as independent prognostic factor of SCLC and NSCLC. 53, 54 These adverse impacts of muscle wasting, imply that obese patients who possess more muscle reserves and muscular strength may become less vulnerable to the detrimental effects of cachexia, thereby having more favorable outcomes. Because patients with sarcopenia were more likely to have a low BMI, patients with higher a BMI are more likely to have a better prognosis. This is likely to explain the increased risk for adverse outcomes and poorer prognosis in underweight or lean patients with lung cancer. 5, 55 However, it should also be cautioned that obesity is a heterogeneous condition, and epidemiological study shows that proportions of fat and lean tissue, especially skeletal muscle, vary widely in current populations. 56 In this respect, a previously overlooked concept is sarcopenic obesity, in which severe obesity and low muscle mass occur simultaneously. 4 Actually, sarcopenic obesity has become a clinically important body composition type, and it was demonstrated that more than 53% of overweight patients with NSCLC were sarcopenic. 57 Evidence is accumulating that sarcopenic obesity is predictive of morbidity and mortality in nonmalignant diseases and cancer, highlighting low lean mass as an unhealthy and unfavorable state for patient survival. 31 For example, in a clinical study examining 2115 patients with solid tumors of the respiratory or gastrointestinal tract, sarcopenic obesity was associated with poorer functional status compared with that of obese patients who did not have sarcopenia, and it was an independent predictor of survival. 57 Moreover, in a recent observational study involving 175 patients with cancer, it was found that obesity predicted higher survival rates only when sarcopenia was absent. 25 Given these findings, it was perhaps not surprising to find higher morbidity and mortality rates in patients with lung cancer and low muscle mass independent of body weight or fat mass. This could explain why, in some clinical studies, no significant differences in lung cancer mortality were observed between obese/overweight and normal weight patients.
Adipose Loss and Muscle-Fat Crosstalk
In addition to reduced muscle mass, fat loss, which occurs in both visceral and subcutaneous depots, is commonly observed in the wasting status of patients with cancer. 46 With cancer progression, the inflammatory mediators secreted from the host and tumor could act on multiple organs to exert negative impacts on host survival. 45 In the context of hypermetabolism and chronic inflammation, increased adipocyte lipolysis and fat oxidation, impaired lipid deposition and adipogenesis, and browning of white adipose tissue may lead to adipose atrophy in cancer. 58 In clinical patients with cancer, fat loss has also been closely associated with reduced quality of life and shorter survival independent of BMI. 58 Therefore, in the metabolically demanding state in lung cancer, overweight and obese patients with higher levels of adipose tissue mass may have more reserves to deal with the wasting condition, which may partially explain the protective effects of excessive body fat tissue in patients with cancer. 5 Additionally, fat tissue may also function as a potential reservoir to dilute the toxic substances in the body, which could buffer the stress of chemotherapy and decrease the rate of death from cancer. 59 Therefore, fat loss may become detrimental in the fight against lung cancer after it has emerged.
Adipose tissue has emerged as an active endocrine and metabolic organ that can have far-reaching interactions with other tissues. 7 Muscle-fat crosstalk has emerged as a novel regulator of energy metabolism, and, interestingly, this interaction seems to drive muscle wasting in the context of cancer cachexia. 60 It was found in cancer cachectic mice that browning of the white adipose tissue took place in the precachectic phase before skeletal muscle atrophy and that blocking such an early event could ameliorate the severity of muscle loss. 61 A previous study in Lewis lung carcinoma-induced cachectic mice also showed that blocking the uncontrolled loss of adipose mass by inhibiting adipose lipolysis could confer protection against the cachectic state and improve survival. 62 These facts suggest that preserving the adipose tissue mass is beneficial to counteract the loss of muscle, thus contributing to attenuate the vicious cycle of wasting. 8 It would therefore be interesting to see whether the generally larger adiposity in obese patients may help preserve the muscle mass, thereby leading to better prognosis in lung cancer.
Clinical Implications and Future Perspectives
Optimizing the Clinical Measurement of Obesity
The link between obesity-related parameters and cancer survival has been the subject of many observational studies. BMI has been used as a major prognostic factor for survival in many types of cancer. However, the mixed data for the association between obesity and mortality in cancer have prompted more attention on the prognostic value of this parameter. BMI does not accurately differentiate between lean and fat tissues, and this limitation may obscure the timely detection of skeletal muscle loss, which may lead to excess mortality in cancer. In addition, BMI alone fails to depict body fat distribution profile (e.g., subcutanenous, visceral) and is not a good measurement to reflect fatness. This is clearly problematic given the existence of obese patients who are metabolically healthy and patients who are metabolically obese but of normal weight. 48 These limitations of BMI in the evaluation of obesity may explain in part the discrepancy in the effect of obesity in lung cancer and many other types of cancer. 9 Given the biological complexity of obesity and current knowledge gaps, dual body weight and body composition assessment seems necessary to provide accurate information about the type and severity of obesity.
Searching for Integrative Prognostic Markers
Obesity is a heterogeneous condition, as evidenced by the large variability of body composition in obese patients with cancer, such as fat distribution patterns, liver fat content, and skeletal muscle mass. 47 Because simple observation of BMI is not adequately powered to characterize patient status and predict cancer outcome, combinatory use of other parameters may be sought to strengthen the predictability of BMI. In this respect, the promise of other anthropometric parameters (e.g., waist circumference, waist-to-hip ratio) that reflect body-fat distribution or lean body mass is under investigation. In a prospective study examining waist circumference and BMI in relation to cause-specific death, it was found that increased abdominal fat measured by waist circumference was related to a higher risk for death from lung cancer and from chronic respiratory disease, independent of BMI. 63 Also, body composition, as assessed on the basis of CT scans, seems to offer more precision, especially in the definition of sarcopenic obesity. 2 Recently, sarcopenia determined by CT was successfully used to predict prognosis in patients with SCLC. In male patients with SCLC treated with first-line chemotherapy or chemoradiotherapy, sarcopenia plus the neutrophil-to-lymphocyte ratio were confirmed as independent predictors of survival and poor tolerance. 64 Another potential source of predictive markers for obese patients with lung cancer is obesity-associated biochemical parameters such as lipid profile and inflammatory biomarkers. Combination of BMI with oxidized low-density lipoprotein receptor 1 has been reported to predict the prognosis of patients with squamous NSCLC. 65 Another interesting example is development of the advanced lung cancer inflammation index, which combines the factors BMI, serum albumin level, and neutrophil-to-lymphocyte ratio to enable an enhanced prediction of survival of patients with advance lung cancer. 66 More recently, a prospective clinical study also reported that inflammatory biomarkers (as measured by the modified Glasgow prognostic score, which combines C-reactive protein and albumin) are superior prognostic factors in advanced lung cancer. 67 The translational landscape of these predictive markers to clinical management of obese patients needs further validation by controlled prospective studies with a large sample size.
Early and Multimodal Intervention on Fat and Muscle Wasting
Patients with lung cancer have been observed to show a relatively high frequency of malnutrition, sarcopenia, and cachexia, 42, 50 which are major adverse factors in treatment failure and shorter survival. Although overweight or obese patients may have more reserves to cope with the wasting condition in the short term, this advantage is very likely to wane with the exacerbation of cachexia. Moreover, if the high mortality risk in patients with lung cancer and sarcopenic obesity is overlooked, the situation could become more adverse for clinical care, emphasizing the urgency of early identification, prompt risk stratification, and intervention.
For patients with signs of precachexia or cachexia, a multimodal intervention is clearly needed to alleviate the wasting of muscle and fat mass. To obtain more useful information about the pathophysiologic status and risk factors of each patient, comprehensive evaluation of body composition, physical function, and nutritional status is of high value. 42 Currently, identification and management of cachexia is largely inadequate, which has become an unmet need in the clinical care of patients with cancer. 68 Current therapies generally show limited efficacy, and new effective drugs are under evaluation. 69 Recently, encouraging data from a clinical trial have been reported for anamorelin, a novel orally active ghrelin receptor agonist, in terms of good tolerance and improvement in lean body mass in patients with NSCLC. 70, 71 The successful development of anamorelin is highly anticipated to help combat the cachexia syndrome in patients with lung cancer. In addition to therapeutic intervention, nutritional and physical activity-based approaches to preserve the muscle and fat mass in obese patients should be actively pursued. For patients with lung cancer and sarcopenic obesity, preemptive nutritional support might be beneficial to improve the surgical and chemotherapeutic outcome. The benefits of resistance training to increase muscle mass in patients with advanced-stage cancer have been demonstrated. 53 Thus, integrating resistance training as part of the treatment modality may help combat the wasting state in patients with lung cancer, especially for those with sarcopenia. Additionally, routine monitoring of change in body weight and body composition is imperative to enable timely assessment of intervention effects during the cancer trajectory and survivorship periods.
Conceptual Update on Weight Control in Lung Cancer Management
Obesity has been linked to increased cancer incidence by a large body of epidemiological data. This fact, as well as some reports of poor survival in obese patients with cancer, has led to much worry regarding overweight or weight gain in the clinic. The unexpected inverse correlation between high body weight and lung cancer mortality in the clinic therefore necessitates rethinking weight control in patients with lung cancer, which is reminiscent of some other chronic diseases such as coronary heart disease and diabetes. 3 As discussed, the seemingly unexpected clinical observations are actually a reflection of an overall protective effect of greater physiological reserve in the form of excess fat and muscle in many chronic diseases, including lung cancer. 5 Such a complicated interaction between host metabolism and cancer is beyond current knowledge, as is illustrated by our growing, yet limited, insight into the heterogeneity of obesity (e.g., sacropenic obesity and metabolically healthy obesity). Before more mechanistic insight is gained to answer this clinical question, update of some common beliefs or perspectives in the scientific community seems necessary. A major implication of the obesity paradox is the potentially different definition of optimal body size in healthy individuals versus those with cancer. With regard to lung cancer, we should recognize that after definite diagnosis, being overweight and even obese may be protective rather than harmful for survival. Accordingly, weight management in patients with lung cancer should be individualized on the basis of cancer stage and body composition. Lean patients should be closely monitored for involuntary weight loss before and after clinical intervention, and a prompt intervention in the complications or malnutrition state is beneficial for improving the long-term survival. In contrast, for overweight or obese patients, aiming for a lean body composition could be a misleading recommendation. Instead, several therapeutic and nontherapeutic strategies may be used to maximally preserve body mass and improve physical fitness. As suggested by the recent proposal "healthy obese versus unhealthy lean," in comparison with weight control per se, greater emphasis might be placed on improving fitness to achieve a metabolically healthy status (e.g., to avoid abdominal obesity and sarcopenia). 72 This conceptual advance deserves more attention in the clinical management of patients with lung cancer.
Conclusions
Despite the confirmed role of obesity in the development of many chronic diseases, including lung cancer, once these conditions have been established, being obese appears to counterintuitively provide protective advantages and even survival benefits. Although controversy surrounds observation of the obesity paradox in patients with lung cancer, such a protective relationship might be regarded more as an underexplored scientific fact than an unexpected paradox. The protective impact of obesity on lung cancer survival underscores the need to differentiate unhealthy and healthy overweight/obese patients and initiate personalized weight management and nutritional support in clinical cancer management. Future mechanistic understanding of this favorable link and its prognostic value is certainly essential for proper risk stratification and optimal clinical outcome. The existing controversies and questions on this reverse relationship reflect the inherent complex link between obesity and lung cancer at the individual level, which deserves clarification by well-designed clinical studies. A combination of therapeutic, nutritional, and lifestyle interventions in a standard guideline is highly expected to optimize the clinical management of patients with lung cancer complicated by obesity, whereby patient benefit could be improved considerably. In the interim, clinical oncologists, thoracic surgeons, and caregivers should keep an open mind regarding these conceptual advances and integrate them into an individualized treatment regimen and medical care in overweight and obese patients. 
